PDSB
PDS Biotechnology CorpEvidence as of 2026-09-11The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on PDSB
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
7-day free trial. AI-written · every claim cites a source · Insight, not advice.
Overview · PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in…
Management team
- Dr. Kirk V. Shepard M.D. · Chief Medical OfficerFind on LinkedIn
- Ms. Deanne Randolph · Head of Investor RelationsFind on LinkedIn
- Mr. Lars Robert Boesgaard M.B.A. · Chief Financial OfficerFind on LinkedIn
- Mr. Sanjay Zaveri · Senior Vice President of Business DevelopmentFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−1.0 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Cautious and the desk’s confidence is moderate. Reported common shares outstanding rose materially from 37,409,137 as of Q3 2024 (fiscal quarter ended 2024-11-07) to 55,971,338 as of Q2 2026 (fiscal quarter ended 2026-08-06), with intermediate counts of 45,395,851 as of FY 2024 (fiscal quarter ended 2025-03-20) and 55,815,653 as of FY 2025 (fiscal quarter ended 2026-03-23). Weighted‑average diluted shares increased from 40,521,001 for the three months ended 2025-03-31 to 55,659,669 for the three months ended 2026-06-30, implying a dilutional effect on per‑share metrics.
Operating results show persistent quarterly losses: net loss by quarter of - 10,178,694 for 2024-07-01 to 2024-09-30, - 9,434,208 for 2025-04-01 to 2025-06-30, - 7,349,056 for 2026-01-01 to 2026-03-31, and - 9,750,575 for 2026-04-01 to 2026-06-30. Operating loss magnitude narrowed from - 10,178,694 in the 2024-07-01 to 2024-09-30 quarter to - 6,496,734 in Q2 2026 (fiscal quarter ended 2026-08-06). Cash and cash equivalents declined from 41,689,591 as of 2024-12-31 to 5,596,254 as of 2026-06-30. Headlines show a 2026-09-08 PIPE of 22.55 million and a same‑date report that a 6 million promissory note was revised to prioritize cash redemption from equity financings; an August 13, 2026 article reported a Q2 2026 loss per share of ( $ 0.18 ), missing the consensus of ( $ 0.13 ) by ( $ 0.05 ).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported common shares outstanding increased from 37,409,137 as of 2024-11-07 to 55,971,338 as of 2026-08-06, showing a material rise in share count over that period.
XBRL companyfacts · 0001140361-24-046891Reported common shares outstanding were 45,395,851 as of 2025-03-20 and 55,815,653 as of 2026-03-23, indicating a continued increase into 2026.
XBRL companyfacts · 0001140361-25-010717Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
No ETF membership, no insider Form 4 filings and no 13F holdings on file.
Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A headline on 2026-09-08 reports PDS Biotechnology secured $22.55 million in PIPE funding and that shares rose 128% premarket.
News · gurufocus.com · 2026-09-08A separate 2026-09-08 headline states PDS Biotechnology revised a $6 million promissory note to prioritize cash redemption from equity financings.
News · kalkinemedia.com · 2026-09-08Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The filings on record don't carry four quarters of both operating cash flow and capital expenditure. IFRS filers report no common capex concept, so no FCF claim is made..
Debate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several claims together support a favorable read: the company secured $22.55M in PIPE funding close to the evidence cutoff and shares reacted strongly, which materially improves near-term liquidity compared with the prior reported cash decline. Operating loss magnitude has narrowed from the earlier quarter to fiscal Q2 2026, indicating improving operating performance on a quarter-to-quarter basis. Street analysts have reiterated buy ratings and multi-firm price targets, which, combined with the financing event and the operating improvement, form a coherent bull narrative that liquidity constraints and operating drag are being addressed. The bear points (share count increase, cash decline, quarterly losses, EPS miss) are relevant but are supported by filings that also document financings and share issuance—evidence strength for the financing and operating-improvement claims is moderate to strong, while the claims about dilution and cash reduction are strong but partially mitigated by the PIPE event and the promissory-note revision.
Chair's verdict, claim by claim
Fragility · computed, not argued
diversified0.23
10 surviving claims rest on 9 distinct sources; the heaviest analyst carries 60% of them, and 100% of what the desk raised survived the debate.
The evidence set rests on a small number of distinct sources with one analyst responsible for a majority of surviving claims, and the desk’s internal debate did not eliminate any items. That concentration and lack of internal falsification mean these claims should be treated as informative but fragile — they carry less independent corroboration than a read built from many equally weighted sources. For decision-making or heavy reliance, users typically seek additional independent confirmations (e.g., subsequent filings or third‑party reconciliations).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
18 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer−1.0 to the score
4 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on PDSB Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.